US LNG exports surge but will buyers in China turn up?
WALTHAM, Mass. - Repligen Corporation (NASDAQ:RGEN), a bioprocessing company with a market capitalization of $6.9 billion and annual revenue of $650 million, has formed a strategic partnership with Austria-based Novasign to integrate machine learning and modeling workflows into Repligen’s filtration systems, according to a press release issued Thursday. According to InvestingPro data, the company maintains a strong financial position with liquid assets significantly exceeding short-term obligations.
As part of the agreement, Repligen will make an investment in Novasign to help the company scale its operations. The collaboration will specifically focus on incorporating Novasign’s modeling technology into Repligen’s tangential flow filtration systems.
The partnership aims to streamline bioprocessing development by enabling real-time predictive control through digital twin technology, potentially reducing development timelines and costs for pharmaceutical manufacturers.
"We are excited to partner with Novasign, a leader in bioprocessing modeling technology," said Ralf Kuriyel, Senior Vice President of Research and Development at Repligen. "By integrating our automated manufacturing systems with smart sensors and Novasign’s digital twins capability, we will provide technology to accelerate process development."
Novasign, founded in 2019 as a spin-off from BOKU University in Vienna, specializes in AI-powered solutions for bioprocessing applications including cultivation, harvest, filtration, and chromatography.
Mark Duerkop, Chief Executive Officer at Novasign, noted that the companies had already collaborated on earlier projects involving Repligen’s process analytical technology.
The partnership represents Repligen’s continued push toward digital manufacturing solutions in the bioprocessing sector, where the company provides technologies for the production of biological drugs. Analysts maintain a positive outlook on Repligen’s prospects, with consensus price targets ranging from $130 to $220 per share. For detailed financial analysis and additional insights, investors can access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 top US stocks.
In other recent news, Repligen Corporation reported its second-quarter earnings for 2025, showcasing mixed financial results. The company’s earnings per share were $0.37, slightly below the anticipated $0.39, which represents a 5.13% shortfall. However, Repligen’s revenue exceeded expectations, coming in at $182 million compared to the forecasted $175.35 million, marking a 3.79% positive surprise. In addition to the earnings report, KeyBanc reiterated its Overweight rating on Repligen, setting a price target of $220.00. The firm cited strong growth in the biological production market as a key factor for this outlook. KeyBanc views Repligen as a benchmark for the overall health of the bioprocessing market, noting that these markets appear to have resumed double-digit growth, which could drive mid-teens growth for the company. These developments provide investors with insights into Repligen’s current and potential future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.